Related Experiment Video

Updated: Aug 1, 2026

The Lambda Select cII Mutation Detection System
07:08

The Lambda Select cII Mutation Detection System

Published on: April 26, 2018

Tofisopam--evaluation of mutagenic and genotoxic properties

B Chłopkiewicz1, A Ejchart, E Anuszewska

  • 1Drug Institute, 30/34 Chełmska Str., 00-725 Warsaw, Poland.

Acta Poloniae Pharmaceutica
|May 24, 2001
PubMed

Insights

Tofisopam, a 2,3-benzodiazepine, showed no mutagenic effects in bacterial tests or genotoxic activity in cell line assays. This study found no evidence of tofisopam causing genetic damage under experimental conditions.

Area of Science:

  • Pharmacology
  • Toxicology
  • Genetics

Background:

  • Tofisopam is a 2,3-benzodiazepine derivative.
  • Assessing the mutagenic and genotoxic potential of pharmaceuticals is crucial for safety.

Purpose of the Study:

  • To evaluate the mutagenic properties of tofisopam using the Ames test.
  • To assess the genotoxic potential of tofisopam on a mammalian cell line.

Main Methods:

  • Ames test utilizing Salmonella typhimurium strains (TA1537, TA97, TA98, TA100, TA102).
  • Cytokinesis-block technique on L929 cell line to assess genotoxicity.

Main Results:

  • No mutagenic activity was detected for tofisopam across all tested bacterial strains.
  • No genotoxic activity was observed in the L929 cell line assays.

Conclusions:

  • Under the tested conditions, tofisopam does not exhibit mutagenic or genotoxic properties.
  • The findings suggest a lack of DNA-damaging potential for tofisopam.

More Related Videos

Use of Frozen Tissue in the Comet Assay for the Evaluation of DNA Damage11:30

Use of Frozen Tissue in the Comet Assay for the Evaluation of DNA Damage

Published on: March 24, 2020

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...